1-Piperonylpiperazine, also known as **1-PP**, is a **chemical compound** that acts as a **potent and selective serotonin 5-HT2A receptor antagonist**.
Here's why it's important for research:
* **Understanding Serotonin Function:** 1-PP is a valuable tool for researchers investigating the role of serotonin in the brain. By blocking the 5-HT2A receptor, it allows scientists to observe the effects of reducing serotonin activity in various neurological processes.
* **Investigating Psychiatric Disorders:** 5-HT2A receptors are implicated in various psychiatric disorders, including depression, anxiety, schizophrenia, and obsessive-compulsive disorder. 1-PP's ability to target these receptors makes it a useful tool for studying the mechanisms underlying these conditions and for developing new therapeutic strategies.
* **Drug Discovery and Development:** 1-PP serves as a lead compound in the development of new drugs targeting the 5-HT2A receptor. By understanding its pharmacological properties and interactions, researchers can modify its structure to create more potent, selective, and effective drugs.
* **Neurological Research:** 1-PP is also used in research on other neurological conditions, including Parkinson's disease, Alzheimer's disease, and epilepsy. Its ability to modulate serotonin signaling pathways may offer insights into the pathogenesis of these disorders and potential therapeutic interventions.
**Important Note:** While 1-PP has significant research value, it is crucial to acknowledge its potential dangers. It can have **significant pharmacological effects** and should only be used by qualified researchers in controlled laboratory settings.
In summary, 1-piperonylpiperazine is a powerful research tool that helps scientists understand the role of serotonin in the brain and explore potential treatments for various neurological and psychiatric conditions. However, it's essential to use it responsibly and with appropriate safety precautions.
1-piperonylpiperazine: coadministration of above cpd attenuates neurotoxicity of 3,4-methylenedioxymethamphetamine; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 94426 |
| CHEMBL ID | 1344680 |
| SCHEMBL ID | 592970 |
| MeSH ID | M0209428 |
| Synonym |
|---|
| HMS1671A08 |
| BB 0249428 |
| 1-benzo[1,3]dioxol-5-ylmethyl-piperazine |
| 1-(3,4-methylenedioxybenzyl)piperazine |
| brn 0885038 |
| piperazine, 1-(3,4-methylenedioxybenzyl)- |
| einecs 250-968-5 |
| 1-piperonylpiperazine, 97% |
| 1-piperonylpiperazine |
| 32231-06-4 |
| smr000554828 |
| 1-(1,3-benzodioxol-5-ylmethyl)piperazine |
| MLS001194789 |
| P1041 |
| 1-[(1,3-benzodioxol-5-yl)methyl]piperazine |
| STK803594 |
| AKOS000119434 |
| NCGC00245839-01 |
| A821205 |
| HMS2871J22 |
| 1-(3,4-methylendioxybenzyl)piperazine |
| unii-512g6r381x |
| 512g6r381x , |
| 5-23-02-00526 (beilstein handbook reference) |
| CCG-104810 |
| FT-0608275 |
| SCHEMBL592970 |
| 1-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine |
| 1-(3,4-methylenedioxybenzyl)-piperazine |
| 1-[(3,4-methylenedioxy)benzyl]-piperazine |
| 4-(3,4-methylenedioxybenzyl)piperazine |
| 4-(3,4-methyenedioxybenzyl)piperazine |
| J50.634F , |
| CHEMBL1344680 |
| piperazine, 1-(1,3-benzodioxol-5-ylmethyl)- |
| 1-(1,3-benzodioxol-5-ylmethyl)piperazine # |
| piperonyl piperazine |
| 1-(1,3-benzodioxol-5-yl-methyl)piperazine |
| methylenedioxybenzylpiperazine |
| mdbzp |
| mfcd00005834 |
| F2190-0512 |
| DTXSID70185994 |
| J-018683 |
| AS-44241 |
| Q6823977 |
| EN300-20509 |
| 1-[(1,3-dioxaindan-5-yl)methyl]piperazine |
| 1-piperonyl piperazine |
| CS-W013142 |
| PD014673 |
| SY033052 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The aim of this work was to evaluate the toxic effects of BZP, MeOPP and MDBP using Caenorhabditis elegans as in vivo model for acute toxicity, development, reproduction and behavior testing." | ( Piperazine designer drugs elicit toxicity in the alternative in vivo model Caenorhabditis elegans. Arbo, MD; Ávila, DS; Bastos, ML; Carmo, H; Cestonaro, LV; Eifler-Lima, V; Garcia, I; Garcia, SC; Göethel, G; Peruzzi, CP; Souto, C, 2020) | 0.56 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0060 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||